evipedia.aidev
← Back

Sulforaphane for Health & Longevity

Evidence Review created on 08/13/2026 using AI4L / Grok 4.5

Also known as: 4-Methylsulfinylbutyl Isothiocyanate, 1-Isothiocyanato-4-(methylsulfinyl)butane, SFN, Sulphoraphane, R-Sulforaphane

Motivation

Sulforaphane is a sulfur-containing compound that forms when broccoli and related vegetables are chopped, chewed, or sprouted. It is of interest because it briefly stresses cells in a way that turns on the body’s own protective enzymes, rather than acting as a direct antioxidant. Health-span-oriented adults look at it as a compact way to raise defenses against air pollutants, metabolic strain, and age-related oxidative wear.

The compound was isolated from broccoli in the early 1990s as a candidate cancer-preventive food factor. Young broccoli sprouts hold far more of its precursor than mature heads. Human trials since then have tested sprout drinks and standardized extracts mainly for pollutant clearance, blood-sugar control, and liver-enzyme changes, with mixed but biologically coherent results.

This review examines the human evidence for and against using sulforaphane as a health and longevity intervention: how it works, what benefits and harms have been measured, who responds, how products differ, and how use is typically structured.

Benefits - Risks - Protocol - Conclusion

High-level overviews that name sulforaphane and treat its protective-enzyme biology in depth.

Peter Attia and Lifespan.io had no dedicated sulforaphane overview as of 13 August 2026; mentions were incidental (diet logs, glutathione background). Life Extension sells broccoli extracts discussed in its magazine; that commercial interest is noted here and in the Conclusion.

Grokipedia

  • Sulforaphane

    A long-form encyclopedia entry covering isolation history, cooking chemistry, protective-enzyme biology, and the clinical-trial landscape in one place.

Examine

  • Sulforaphane

    Examine’s supplement monograph summarizes human evidence, dose estimates from rodent scaling, and a research feed of recent trials.

ConsumerLab

No dedicated ConsumerLab article for sulforaphane was found. Mentions appear only inside broader Q&A pages and clinical updates, not as a primary review of the compound.

Systematic Reviews

Human systematic reviews of sulforaphane cluster around cancer randomized controlled trials (RCTs), autism spectrum disorder (ASD) scores, chemical-toxicant protection, brassica–thyroid safety, and whether dietary phytochemicals activate Nrf2 (nuclear factor erythroid 2–related factor 2, the cell’s master switch for protective genes) in people.

Mechanism of Action

Sulforaphane is an isothiocyanate (a reactive sulfur-containing plant molecule) formed when glucoraphanin, its stable precursor, is cleaved by myrosinase (a plant β-thioglucosidase) or by related enzymes in the gut microbiota. Heat inactivates plant myrosinase; mustard-seed powder can restore conversion after cooking. The intact molecule is an electrophile that covalently modifies cysteine residues on Keap1 (Kelch-like ECH-associated protein 1, the cytosolic repressor that marks Nrf2 for destruction). Freed Nrf2 (nuclear factor erythroid 2–related factor 2, the master switch for cellular defense genes) enters the nucleus, binds antioxidant-response elements, and raises phase II enzymes including NQO1 (NAD(P)H:quinone oxidoreductase 1) and glutathione S-transferases. It is a selective, monofunctional inducer: it raises those phase II enzymes without inducing aryl-hydrocarbon-receptor-dependent cytochromes P450.

It also inhibits histone deacetylases (enzymes that tighten chromatin and silence genes) after a sprout meal. Sulforaphane also dampens NF-κB (nuclear factor kappa B, a central inflammatory transcription factor).

After oral intake, peak plasma isothiocyanate/dithiocarbamate levels occur at about 1 hour and decline with a half-life of 1.77 ± 0.13 hours. Metabolism follows the mercapturic-acid pathway: glutathione conjugation, then conversion to cysteine and N-acetylcysteine conjugates excreted in urine. About 58% of a free-isothiocyanate dose appears in urine by 8 hours, versus 18–20% after glucoraphanin. Metabolites appear in prostate and airway tissue. A competing view holds that durable Nrf2 activation can protect already-transformed cells—most relevant when tumors already carry KEAP1 or NFE2L2 (the gene that encodes Nrf2) mutations.

Historical Context & Evolution

Sulforaphane was isolated in 1992 by Zhang, Talalay, Cho, and Posner at Johns Hopkins as the principal monofunctional inducer of quinone reductase in broccoli (Brassica oleracea var. italica). The measured finding was selective induction of phase II detoxication enzymes without induction of aryl-hydrocarbon-receptor-dependent cytochromes P450. The original intended use was cancer chemoprotection: accelerate disposal of electrophiles from food and the environment.

In 1997 Fahey, Zhang, and Talalay reported that 3-day broccoli sprouts contain 10–100 times the inducer activity of mature heads. That result, not later commentary, is what launched sprout beverages and standardized extracts. Field trials in Qidong, China, then tested whether those preparations changed handling of aflatoxin and urban air pollutants. The 2014 randomized beverage trial found 61% higher urinary benzene conjugates and 23% higher acrolein conjugates versus placebo, with no fall-off in bioavailability over 12 weeks.

Interest widened to hepatic glucose output, neuroinflammation, and prostate-specific antigen kinetics. Small randomized trials in type 2 diabetes, autism, schizophrenia, and former smokers followed. Commercial products split into glucoraphanin-plus-myrosinase tablets and stabilized free sulforaphane; some trace to Brassica Protection Products, a company linked to the original Johns Hopkins group.

Current opinion is not a closed consensus. Human biomarker trials are positive more often than hard clinical endpoints. Dose, myrosinase status, and gut microbes explain much of the scatter. Newer work asks whether Nrf2 activation remains desirable once a tumor is established—an open mechanistic question, not a verdict.

Expected Benefits

Medium 🟩 🟩

Enhanced Detoxification of Airborne Pollutants

A 12-week randomized trial in 291 adults found that a daily sprout beverage (600 µmol glucoraphanin plus 40 µmol sulforaphane) raised urinary glutathione conjugates of benzene by 61% and acrolein by 23% versus placebo. An earlier 50-person crossover in the same high-pollution region showed 20–50% increases after either a sulforaphane-rich or a glucoraphanin-rich drink. The mechanism is Nrf2-driven induction of glutathione S-transferases. Endpoints were exposure biomarkers, not lung-disease events. (Egner et al., 2014; Kensler et al., 2012)

Magnitude: Urinary benzene mercapturic acid +61% and acrolein +23% versus placebo over 12 weeks at 600 µmol glucoraphanin plus 40 µmol sulforaphane daily.

Improved Glycemic Control ⚠️ Conflicted

Broccoli-sprout extract providing 150 µmol sulforaphane lowered fasting glucose and glycated hemoglobin in obese adults with poorly controlled type 2 diabetes (7.04% versus 7.38% on placebo at 12 weeks). A later prediabetes trial missed its 0.3 mmol/L target (overall −0.2 mmol/L; larger only in a gut-microbe subset). Smaller powder trials reported lower HOMA-IR (a fasting insulin-resistance index) at 10 g/day. Results diverge by phenotype and conversion. (Axelsson et al., 2017; Dwibedi et al., 2025; Bahadoran et al., 2012)

Magnitude: In obese, poorly controlled type 2 diabetes, glycated hemoglobin 7.04% versus 7.38% on placebo (0.34 percentage points; 53.4 versus 57.1 mmol/mol) and fasting glucose 8.2 versus 8.9 mmol/L at 12 weeks; the prediabetes primary endpoint was not met (0.2 mmol/L).

Lower LDL Cholesterol from High-Glucoraphanin Broccoli

Two independent 12-week randomized diet trials (n = 37 and n = 93) assigned 400 g/week of high-glucoraphanin broccoli or standard broccoli. High-glucoraphanin broccoli lowered plasma LDL cholesterol (low-density lipoprotein, the cholesterol fraction that builds up in arteries) by 7.1% and 5.1%; standard broccoli changes were not significant. Combined, the high-glucoraphanin diet outperformed standard broccoli. Isolated sulforaphane capsules were not tested. (Armah et al., 2015)

Magnitude: LDL-C −7.1% (95% confidence interval −12.3 to −1.8) and −5.1% (95% confidence interval −8.1 to −2.1) with 400 g/week high-glucoraphanin broccoli for 12 weeks.

A 2025 meta-analysis of six RCTs reported small improvements in total autism scores (standardized mean difference −0.27, a pooled effect size across rating scales) and social interaction. The 2014 young-adult trial was positive; a later pediatric trial in ages 3–7 was not. Adverse-event rates matched placebo. This is a documented human signal, not a longevity endpoint. (Wang et al., 2025; Singh et al., 2014)

Magnitude: Standardized mean difference −0.27 for total symptoms (95% confidence interval −0.42 to −0.12); pediatric results include a null trial.

Low 🟩

Reduced Hepatic Injury Markers

In 52 men with fatty liver, 30 mg/day glucoraphanin for 2 months lowered median ALT (a liver-injury enzyme) from 54.0 to 48.5 IU/L and reduced urinary 8-OHdG (an oxidative DNA-damage marker). An unstandardized extract trial in women was null. (Kikuchi et al., 2015)

Magnitude: Median ALT 54.0 → 48.5 IU/L after 2 months of 30 mg/day glucoraphanin, with correlated 8-OHdG decline; placebo unchanged.

Slower PSA Rise After Prostatectomy

In 78 men with rising PSA after surgery, 60 mg/day free sulforaphane for 6 months missed its primary slope target. Mean PSA rose +0.099 versus +0.620 ng/mL on placebo, and doubling time lengthened 86%. (Cipolla et al., 2015; Alumkal et al., 2015)

Magnitude: Mean PSA +0.099 versus +0.620 ng/mL; doubling time 28.9 versus 15.5 months; primary log-slope endpoint not met.

Faster Processing Speed in Older Adults

A 12-week trial in 144 older adults found that sulforaphane improved processing speed and working memory versus placebo. Combining it with a brain-training game added no further gain. This is a single trial with a commercial supplement partner. (Nouchi et al., 2021)

Magnitude: Directionally improved processing speed and working memory after 12 weeks versus placebo; the report does not give a single conventional-unit effect size for the sulforaphane-only arm.

Reduced H. pylori Colonization Markers

A randomized trial in 48 infected adults found that 70 g/day broccoli sprouts for 8 weeks lowered urea-breath and stool-antigen markers versus alfalfa-sprout placebo. Levels returned 2 months after stopping. Eradication was not shown. (Yanaka et al., 2009)

Magnitude: Directionally lower urea-breath and stool-antigen levels after 8 weeks of 70 g/day sprouts, with rebound after a 2-month washout; the literature reports no conventional-unit outcome figure for those markers.

Speculative 🟨

Slowing of Neurodegenerative Processes

Rodent Alzheimer and stroke models show less neuronal injury after Nrf2 activation. Human neurodegenerative outcome trials are absent; the basis is mechanistic and preclinical only.

Skin Photoprotection

Topical and oral sulforaphane induce skin phase II enzymes and can blunt ultraviolet erythema in small human studies. Controlled aging-outcome trials are lacking; the basis is mechanistic plus short pharmacodynamic work.

Cancer Chemoprevention

The original claim is faster carcinogen disposal and fewer rodent tumors. Human cancer RCTs show biomarker shifts without consistent survival or PSA wins. The basis is mechanistic plus inconsistent clinical endpoints. (ElKhalifa et al., 2023)

Benefit-Modifying Factors

  • GSTM1 / GSTT1 genotype: GSTM1-null adults (missing glutathione S-transferase M1, a conjugating enzyme; GSTT1 is a related often-deleted gene) show higher plasma metabolite area-under-the-curve after broccoli. (Gasper et al., 2005)

  • Gut microbiota: Prediabetes responders carried more Bacteroides genes that convert glucoraphanin to sulforaphane; serum levels tracked that operon. Precursor-only products depend on this conversion. (Dwibedi et al., 2025)

  • Baseline glycemia and adiposity: The clearest fasting-glucose signal was in obese adults with poorly controlled type 2 diabetes, not in well-controlled or lean prediabetes. (Axelsson et al., 2017)

  • Sex: Thyroid-safety data are from women; the Kikuchi liver trial enrolled men. Sex-specific efficacy is not established.

  • Age: Cognitive-speed data are from older adults. Detoxification trials enrolled working-age adults. No separate dose has been defined for the eighth decade.

  • Myrosinase and food matrix: Cooked crucifers without added mustard seed yield little sulforaphane. Active myrosinase, or a free-sulforaphane product, dominates benefit size more than labeled milligrams.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal Intolerance

Gas, bloating, nausea, and loose stools are the adverse events that actually appear in sprout and extract trials. A phase I in-patient study of repeated glucoraphanin or isothiocyanate doses found no laboratory toxicity. The 2025 prediabetes trial reported gastrointestinal side effects without severe events. A cancer-RCT systematic review found no significant adverse-event difference versus controls. Severity is usually mild and stops with dose reduction or discontinuation. (Shapiro et al., 2006; Dwibedi et al., 2025; ElKhalifa et al., 2023)

Magnitude: Directionally more gastrointestinal events than placebo in broccoli-sprout extract trials; literature reports no pooled incidence figure across formulations.

Low 🟥

Thyroid Function Change ⚠️ Conflicted

Brassica foods can interfere with iodine uptake in iodine-deficient animals. A 12-week trial in 45 women found no change in TSH (thyroid-stimulating hormone) or free T4 (thyroxine). A 2024 review found no human thyroid harm when iodine is adequate. (Chartoumpekis et al., 2019; Galanty et al., 2024)

Magnitude: No change in TSH, free T4, or thyroglobulin after 84 days of a sulforaphane/glucoraphanin beverage in 45 women; animal goitrogen signals do not clearly translate.

Altered Drug-Metabolizing Enzyme Activity

In vitro, sulforaphane can inhibit CYP3A4 (the main liver drug-clearance enzyme) and antagonize PXR (pregnane X receptor). A human crossover at 450 µmol/day did not block rifampicin-induced CYP3A4 activity and showed no cohort-wide effect of sulforaphane alone. (Poulton et al., 2013)

Magnitude: Midazolam area under the curve was unchanged for the full cohort at 450 µmol/day; rifampicin still cut midazolam exposure by 70% when combined with sulforaphane.

Bacterial Contamination of Home-Grown Sprouts

Warm, humid sprouting can amplify Salmonella or E. coli present on seed. Outbreaks from eaten seed sprouts are documented internationally. Standardized capsules avoid this exposure. Severity can be serious in older adults. (Miyahira & Antunes, 2021)

Magnitude: Directionally higher foodborne-illness risk with raw home sprouts than with capsules; literature reports no sulforaphane-specific incidence figure.

Speculative 🟨

Protection of Established Nrf2-High Tumors

Constitutive Nrf2 can make cancer cells more chemoresistant in cell models. Whether dietary sulforaphane doses do this in people with KEAP1-mutant tumors is untested; the basis is mechanistic. (Wang et al., 2008)

Hypersensitivity to Brassica Preparations

Isolated allergic reactions to broccoli or sprout preparations are reported anecdotally. Controlled incidence data do not exist; the basis is isolated reports.

Risk-Modifying Factors

  • Iodine status: Goitrogen concern concentrates in iodine deficiency. Adequate iodine intake is the factor that tracks with null thyroid findings in human brassica studies.

  • Baseline TSH: Starting TSH already above the laboratory range is the group in which a theoretical further rise would matter; 12-week beverage data did not move TSH in euthyroid (normal-thyroid) women.

  • Sex: Autoimmune thyroid disease is more common in women; the dedicated beverage safety analysis enrolled women only.

  • Pre-existing gut disease: Irritable bowel, FODMAP (poorly absorbed fermentable carbs) sensitivity, or inflammatory bowel disease amplify sprout-related gas more than capsule extracts.

  • Age: Older adults with polypharmacy and reduced glutathione reserves may feel gut effects at lower sprout volumes; no age-specific toxicity signal is documented.

  • Tumor Nrf2 genotype: KEAP1 or NFE2L2 gain-of-function tumors are the mechanistic setting for the chemoresistance concern; it is untested at food or supplement doses.

Key Interactions & Contraindications

  • CYP1A2 substrates (theophylline, clozapine, tizanidine): Moderate caution. CYP1A2 is a liver enzyme that clears several drugs. In vitro work suggests slowed clearance; human magnitude is unquantified. Monitor levels if both are started.

  • CYP3A4 substrates (midazolam, simvastatin, amlodipine): Caution, not an absolute bar. A human midazolam probe found no cohort-wide CYP3A4 change at 450 µmol/day. (Poulton et al., 2013)

  • Chemotherapy (cisplatin, doxorubicin, etoposide): Caution in Nrf2-high tumors. Cell work shows Nrf2 can blunt cytotoxicity; whether food-range sulforaphane does this in people is unknown.

  • Acetaminophen: Monitor. Shared glutathione conjugation could, in theory, alter handling at high acetaminophen doses; clinical interaction trials are lacking.

  • Thyroid hormone (levothyroxine): Caution when iodine is low or TSH is already high. Human beverage data did not change thyroid tests over 12 weeks.

  • Other Nrf2 activators (curcumin, bardoxolone-class agents): Caution. Additive cellular-stress signaling may increase gut irritation; no human trial defines a combined ceiling.

  • Mustard-seed myrosinase with glucoraphanin products: Potentiating, usually intended. Raises conversion and therefore both benefit and gut load.

Populations who should avoid Sulforaphane:

  • Known allergy to broccoli, mustard, or other brassica preparations
  • Active cytotoxic chemotherapy for a documented KEAP1- or NFE2L2-mutant solid tumor, unless the oncology team is directing use
  • Concentrated extracts in pregnancy (food-range crucifers are a different exposure; extract teratology data are insufficient)
  • Uncontrolled hypothyroidism plus documented iodine deficiency at high raw-sprout intakes (>100 g/day)

Risk Mitigation Strategies

  • Start low, food first: Begin with 20–40 g fresh 3–5-day broccoli sprouts or one glucoraphanin-plus-myrosinase tablet to limit gas and loose stools.

  • Split the serving: Dividing a daily sprout or extract amount across two meals reduces peak gut load from a short-half-life compound.

  • Confirm iodine intake: Keep dietary iodine near 150 µg/day before large raw-sprout intakes to address the theoretical goitrogen concern.

  • Prefer tested extracts if FODMAP-sensitive: Standardized capsules avoid the fiber load of 50–100 g sprouts that drives bloating.

  • Hold concentrated extracts around cytotoxic chemotherapy: Pause non-prescribed Nrf2 activators during active cycles to avoid theoretically protecting Nrf2-high tumors from the chemotherapy.

  • Home-sprout hygiene: Use clean seed, rinse 2–3 times daily, and refrigerate after day 3–5 to cut bacterial contamination risk.

Therapeutic Protocol

  • Food-first sprouts (Patrick / Fahey teaching): About 40–100 g fresh 3–5-day broccoli sprouts daily, chewed well, often in the morning with food.

  • Glucoraphanin plus myrosinase (Avmacol-type; many U.S. trials): Typical labeled yield is about 30–60 mg glucoraphanin with active enzyme, once daily.

  • Stabilized free sulforaphane (Prostaphane-type; Cipolla protocol): 10–60 mg free sulforaphane daily; the biochemical-recurrence trial used 60 mg for 6 months.

  • Time of day: Morning with food is the usual pattern. The 1.8-hour half-life argues against late-day “coverage”; some users split morning and midday.

  • Single versus split: Free sulforaphane is often taken once daily. Precursor-plus-enzyme products are sometimes split if gut symptoms appear.

  • Half-life: Plasma isothiocyanate/dithiocarbamate half-life is 1.77 ± 0.13 hours; peak at about 1 hour. (Ye et al., 2002)

  • Genetics: GSTM1-null adults clear metabolites faster; they may need consistent daily intake rather than infrequent large servings.

  • Sex: No validated sex-specific dose. Thyroid monitoring is more often discussed in women because autoimmune thyroid disease is more prevalent.

  • Age: Older adults often start at the low end (one tablet or ~40 g sprouts) because polypharmacy and gut reserve differ.

  • Baseline labs: Higher fasting glucose or fatty-liver enzymes are the settings with human outcome signals; they do not by themselves set a higher starting dose.

  • Pre-existing disease: Active inflammatory bowel disease or FODMAP intolerance favors a myrosinase-containing capsule over large sprout volumes.

Discontinuation & Cycling

  • Duration intent: Used as a long-horizon health-span practice, not a defined course. Human trials last 4 weeks to 12 months; no lifelong safety series exists.

  • Withdrawal: No withdrawal syndrome is described. Enzyme induction fades over days as the short-half-life compound clears.

  • Taper: A taper is not required. Stopping after gut intolerance is the usual exit.

  • Cycling: Some clinicians use 5 days on / 2 days off to limit Nrf2 feedback; Fahey-style teaching is often daily and continuous. Neither schedule has a head-to-head trial.

  • After a break: Restart at the previously tolerated amount; re-titration from a half serving is used only if the last stop was for gut symptoms.

Sourcing and Quality

  • Formulation type: Products are precursor (glucoraphanin), precursor plus myrosinase, or stabilized free sulforaphane. Labels that list only “broccoli sprout extract” milligrams without a yield are not comparable.

  • Myrosinase activity: Heat-processed seed extracts without added active enzyme convert poorly. Look for stated myrosinase or a measured sulforaphane yield after incubation.

  • Third-party testing: Prefer lots with ISO-accredited assay of glucoraphanin or sulforaphane, plus microbial and heavy-metal screens. ConsumerLab has no dedicated sulforaphane review.

  • Named preparations used in trials: Avmacol / Avmacol Extra Strength (Nutramax) appears in several U.S. protocols. Prostaphane is the free-sulforaphane product used by Cipolla. Jed Fahey has disclosed a historical tie to Brassica Protection Products, which supplies broccoli-seed extract to several brands.

  • Fresh sprouts: Use seed sold for sprouting, not garden seed treated with fungicide. Three to five days of growth is the usual window of high glucoraphanin.

  • Cooking rescue: Light steaming of mature broccoli plus mustard-seed powder restores conversion when raw sprouts are not used.

Practical Considerations

  • Time to effect: Urinary pollutant conjugates rise within days. Glucose and liver-enzyme shifts, when they occur, are measured at 8–12 weeks. There is no established “felt” onset.

  • Common pitfalls: Swallowing cooked broccoli without a myrosinase source; trusting unlabeled sprout capsules; growing sprouts in standing water; equating 500 mg “broccoli extract” with 50 mg sulforaphane.

  • Regulatory status: Sold as a dietary supplement or food in the United States, not as an FDA-approved drug. Disease-treatment claims on sprout powders have drawn FDA warning letters.

  • Cost and access: Homegrown sprouts are inexpensive. Stabilized free sulforaphane is the costly form. Neither is typically covered by insurers.

  • Taste and adherence: Fresh sprouts are pungent. Capsules avoid flavor but not always gut effects.

Interaction with Foundational Habits

  • Sleep: Indirect, none established as disruption. Nrf2 expression is circadian in model systems; human sleep-architecture trials are absent. Morning dosing avoids any theoretical evening alerting from a cellular-stress signal.

  • Nutrition: Direct and potentiating. Conversion needs myrosinase or a capable microbiota. Light steam plus mustard seed raises yield; long boiling destroys it. High raw-sprout volumes add FODMAP load.

  • Exercise: Uncertain, possibly potentiating. Both exercise and sulforaphane engage redox-adaptive programs. A recruiting crossover is testing short-term sulforaphane plus exercise on immunometabolism (NCT07668596).

  • Stress management: Indirect overlap. Heat, fasting, and sulforaphane all engage Nrf2; no trial shows added cortisol change. Stacking several brief cellular-stress inputs in one day is a gut- and fatigue-limited choice, not a documented synergy.

Monitoring Protocol & Defining Success

Baseline work before first concentrated use typically includes fasting glucose and glycated hemoglobin, a liver panel, TSH with free T4 if thyroid disease is already known, and high-sensitivity C-reactive protein as a general inflammation marker. Men already followed for prostate disease continue PSA. There is no routine clinical blood level for sulforaphane; research groups sometimes measure urinary dithiocarbamates as an exposure check.

Ongoing labs are useful at 4–8 weeks, then every 6–12 months if use continues. Glucose and liver enzymes are the endpoints with human trial signals. Thyroid tests matter mainly when iodine intake is low or autoimmune thyroid disease is already known. Qualitative markers—gastrointestinal comfort, energy, and mental clarity—are recorded in parallel, because most people stop for gut symptoms long before a laboratory value moves.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting glucose 70–85 mg/dL (3.9–4.7 mmol/L) Tracks the human glycemic signal Conventional goal is usually <100 mg/dL; fast 8–12 h
Glycated hemoglobin 4.6–5.3% 2–3 month glucose average HbA1c (glycated hemoglobin); conventional prediabetes cut is 5.7%; not a fasting test
ALT <25 U/L (men), <19 U/L (women) Liver-injury enzyme moved in one RCT Conventional upper limits are often ~40 U/L
GGT <20–30 U/L Oxidative and hepatic context Gamma-glutamyl transferase; pair with ALT; alcohol and medications also raise it
TSH 0.5–2.5 mIU/L Thyroid safety check Conventional range is about 0.4–4.5; add free T4 if abnormal
hs-CRP <0.7 mg/L General inflammatory load High-sensitivity C-reactive protein; conventional “average risk” is <3.0 mg/L; avoid during acute illness
Urinary 8-OHdG Change from the person’s own baseline Oxidative DNA-damage marker used by Kikuchi No single functional target; 24-h or creatinine-normalized
PSA (if already followed) Individualized; slope versus the person’s own baseline Biochemical-recurrence kinetics Not a screening add-on for sulforaphane users without prostate disease
  • Sleep quality and next-day alertness
  • Gastrointestinal comfort (gas, stool form, nausea)
  • Fasting energy and post-meal clarity
  • Training recovery and perceived exertion
  • Skin reactivity after sun exposure, if photoprotection is a personal goal

Emerging Research

  • Psychosis-risk prevention: The phase 3 DROPS trial is randomizing 300 clinical high-risk participants to sulforaphane or placebo (NCT03932136). A clear null would weaken the neuropsychiatric case; a positive conversion result would extend it beyond autism scores.

  • Anthracycline heart protection: A recruiting phase 1/2 trial is testing whether sulforaphane limits doxorubicin cardiomyopathy (heart-muscle injury from anthracyclines, a chemotherapy class) in 70 people with breast cancer (NCT03934905). Benefit would support Nrf2 as a cardioprotective lever; harm would feed the chemotherapy-interaction concern.

  • Melanoma prevention: A not-yet-recruiting phase 2 trial will compare sulforaphane with placebo in 120 people with prior melanoma (NCT07040280). Incidence data could move skin claims off the speculative tier.

  • Airway histopathology in former smokers: Twelve months of a ~95 µmol/day sulforaphane product did not reverse bronchial histopathology, though Ki-67 (a proliferation marker) fell about 20% versus a rise on placebo (Yuan et al., 2025; NCT03232138). That completed result trims expectations for structural chemoprevention.

  • Exercise immunometabolism: A recruiting crossover (n = 20) pairs short-term sulforaphane with exercise (NCT07668596). A null on mitochondrial or inflammatory readouts would argue against stacking it with training for extra redox effect.

Conclusion

Sulforaphane is a short-lived sulfur compound formed from broccoli and its sprouts. In humans it raises the cell’s own protective-enzyme program, speeds urinary disposal of some urban air pollutants, and in selected metabolic settings nudges fasting glucose and liver-enzyme markers in a favorable direction. Those signals sit on small, short randomized trials built around blood or urine markers rather than hard disease events.

The same record is uneven. Sprout-drink work shows faster clearance of benzene and acrolein. Glucose trials do not all meet their pre-set targets; the clearest drop was in obese adults with poorly controlled type 2 diabetes. Cancer-treatment trials have not produced consistent prostate-antigen or survival wins. Gastrointestinal discomfort is the adverse event that actually appears. A worry that brassica compounds suppress the thyroid has not shown up in controlled beverage studies when iodine is adequate.

Product quality matters more than dose charts imply. Missing conversion enzyme, and conversion that depends on gut microbes, can turn a labeled precursor serving into little absorbed compound. Independent academic groups and commercially linked investigators both publish here; product-specific claims from the latter deserve the same scrutiny as other sponsored work.

For a risk-aware adult already optimizing sleep, food, and training, sulforaphane is a plausible add-on with a thin but biologically coherent human record, not a proven longevity drug. The main trade-off is modest, reversible gut irritation against marker changes that have not been shown to extend healthy years.

Top - Benefits - Risks - Protocol